Durable Medical Equipment Market Size to Reach USD 461.65 Billion by 2035 | SNS Insider

North America leads the Durable Medical Equipment market, accounting for 35% of global volume in 2025, with the U.S. valued at $74.62B and Europe at $67.80B. Long-term growth is supported by Medicare reimbursement, remote patient monitoring, connected medical devices, and rising home healthcare adoption.

Analysis

The investable signal is less about the headline market size and more about where margin pools migrate: toward companies that monetize recurring supplies, data, and reimbursement code complexity rather than one-time hardware. That favors names with sticky installed bases in sleep, diabetes, and respiratory care, where every incremental device sold can pull through years of consumables and service revenue. The second-order winner is remote monitoring software that can reduce provider labor per patient and widen switching costs; the loser set is more likely to be acute-care equipment channels and hospital-centric vendors that see some utilization shift to home settings.

The key risk is payer pushback, not demand. If Medicare or Medicare Advantage tightens utilization management, growth can persist while gross margins and cash conversion disappoint because volume gets normalized through prior auth, audit pressure, or lower allowable rates. Over the next 1-3 quarters, the catalyst path is CMS language and reimbursement commentary; over 6-18 months, the thesis only holds if connected-device attach rates and replacement cycles outpace reimbursement compression. A reversal would show up first in slower script growth or lower same-store supply usage, not in market share headlines.

Consensus is probably overstating the simplicity of the secular story. The market often pays up for 'home care adoption' without underwriting how much of that growth is subsidized by government reimbursement and how quickly bidding dynamics can erode unit economics. This looks like a slow-burn relative-value theme, not a clean standalone event trade; absent a company-specific catalyst, the best expression is to wait for dislocations rather than chase the sector basket.

Key Decisions for Investors

• Watchlist long: RMD / PODD / DXCM on any 5-8% pullback; only add if upcoming reimbursement commentary stays stable, with a 6-18 month thesis on recurring consumables and data moats.
• Relative-value pair: long a home-care/DME basket (RMD, PODD, DXCM) vs. short HCA or THC for 1-3 months if CMS and Medicare Advantage commentary indicates continued site-of-care shift; stop if utilization data re-accelerates in hospitals.
• Do not force a sector-wide long in XLV or IHI here; the signal is too generic and there is no event catalyst, so keep this as an alert rather than a position unless company guidance confirms margin expansion.
• Set a hard watch item on CMS reimbursement updates and payer audit intensity; thesis is falsified if supplier growth holds but EBITDA margins compress or if managements flag prior-auth friction within the next 1-2 quarters.